Twist Bioscience launches monkeypox virus DNA controls

Jul. 14, 2022 9:26 AM ETTwist Bioscience Corporation (TWST)By: Dania Nadeem, SA News Editor
  • Twist Bioscience (NASDAQ:TWST) said on Thursday it launched two human monkeypox virus synthetic DNA controls.
  • (TWST) stock rose ~4% before the bell.
  • The monkeypox synthetic DNA controls are designed based on specific monkeypox clades, cover over 80% of the full viral genome and are sequence-verified using next-generation sequencing (NGS) and polymerase chain reaction (PCR).
  • DNA controls are powerful tools in finding genomic DNA methylation and epigenomic research.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.